Prime Medicine Revenue and Competitors
Estimated Revenue & Valuation
- Prime Medicine's estimated annual revenue is currently $53M per year.
- Prime Medicine's estimated revenue per employee is $155,000
- Prime Medicine's total funding is $155M.
- Prime Medicine's current valuation is $1.2B.
Employee Data
- Prime Medicine has 342 Employees.
- Prime Medicine grew their employee count by -88% last year.
Prime Medicine's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Interim CFO and Chief Accounting Officer | Reveal Email/Phone |
3 | VP Clinical Science | Reveal Email/Phone |
4 | SVP, Head Strategy and Corporate Operations | Reveal Email/Phone |
5 | Head Global Gene Therapy Research | Reveal Email/Phone |
6 | Head Talent Acquisition | Reveal Email/Phone |
7 | SVP, IP & Legal Affairs | Reveal Email/Phone |
8 | SVP, Head Clinical | Reveal Email/Phone |
9 | VP Research | Reveal Email/Phone |
10 | Head Human Resources | Reveal Email/Phone |
Prime Medicine Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $67.7M | 549 | 1% | $689M | $4.6B |
What Is Prime Medicine?
Prime Medicine, Inc. was founded in 2019, developed in the lab of David Liu, PhD, a founder of the company, and funded by several prominent investors. Prime Medicine aspires to change the practice of medicine by curing diseases through the advancement of a new genome-editing approach called "prime editing," an innovative technology that enables highly flexible rewriting of DNA sequences. It is a versatile and precise genome editing method that can make nearly any local alteration to precisely-targeted DNA sequences and has the potential to correct almost all disease-causing mutations. Engineered prime editors are modified Cas9 proteins coupled to reverse transcriptases. Prime editors use a new type of engineered guide RNA, called a pegRNA, that directs them to target DNA and also encodes the desired DNA edit. At the target DNA site, the modified Cas9 cuts one strand of the DNA, which the molecular complex uses to "prime," or initiate, the reverse transcription of the edited genetic information carried by the pegRNA directly into the genome.
keywords:N/A$155M
Total Funding
342
Number of Employees
$53M
Revenue (est)
-88%
Employee Growth %
$1.2B
Valuation
N/A
Accelerator
Prime Medicine News
Medical device manufacturer IGIN Smart Technologies is in talks over ... former Romanian Prime Minister Victor Ponta, and former Belgian...
A "Prime" Time Genetic Medicine Deal for Cancer and Autoimmune Therapies. Published: Mar 31, 2022 By Vanessa Doctor, RN. Partnerships/financial.
Myeloid Therapeutics and Prime Medicine have signed an exclusive option and research collaboration agreement to advance the development of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $53M | 342 | 16% | N/A |
#2 | $47.3M | 352 | 5% | $520M |
#3 | $109.5M | 356 | -46% | N/A |
#4 | $65.4M | 361 | N/A | N/A |
#5 | $63.4M | 362 | 7% | N/A |